Academic literature on the topic 'Zhuan min gong hui'

Abstract The therapeutic efficacy of CAR-T cells in solid tumors, unlike in hematologic tumor, is greatly limited by the insufficient infiltration and persistence of CAR-T cells as well as the immunosuppressive tumor microenvironment. The aim of this study was to overcome these obstacles by introducing an αPDL1/CD28 switch-receptor construct and by seeking combinatorial strategies for CAR-T cells in solid tumors. We found that in non-transduction T cells, the cytokine release and T cell proliferation were repressed in response to PD-L1 protein, while T cells that express αPDL1/CD28 switch-receptor showed enhanced functions, indicating that αPDL1/CD28 could revert PD-L1 inhibition into CD28 costimulation. CAR-T cells with αPDL1/CD28 switch-receptor showed better effector function than that of unitary CAR-T in vitro studies and significant responses in tumor-bearing mice, with more effector memory T cells infiltrated in the tumor. On this basis, PD-1 inhibitor can further enhance the efficacy and persistence of αPDL1/CD28 CAR-T cells, especially in PDL1+ tumor models. We found in vitro studies that radiotherapy increased the expression of T-cell recruiting chemokines and promoted CAR-T cell transmigration. In tumor-bearing mice, synergistic anti-tumor efficacy of mice treated with radiotherapy and αPDL1/CD28 CAR-T cells was further observed. Finally, triple therapy with radiotherapy and anti-PD1 plus αPDL1/CD28 CAR-T cells maximized antitumor responses and induced complete cures in the tumor-bearing mice. Our study suggests that αPDL1/CD28 augments the function of CAR-T cells, and the combinatorial regime of αPDL1/CD28 CAR-T cells, radiotherapy and anti-PD1 in solid tumors could be further investigated. Citation Format: Limei Yin, Wenbo Wang, Zhuoran Yao, Jianxin Xue, Ruizhan Tong, Hui Wang, Shuangsi Liao, Laduona Wang, Yue Zheng, Feifei Na, Min Yu, Xuanwei Zhang, Youling Gong, Meijuan Huang, Xianming Mo, Chong Chen, You Lu. CAR-T cells with αPDL1/CD28 switch-receptor synergize radiotherapy and anti-PD1 therapy in solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5569.

Abstract Background: The IMpower133 represented the current standard of care in the 1L setting for patients (pts) with ES-SCLC (extensive-stage small cell lung cancer). However, there are still unmet needs for ES-SCLC treatment. LDRT could play a key role in the priming effect of immune system by acting as an immune adjuvant and having sensitive cytotoxic activity to SCLC. The interim analysis of MATCH study after stage I showed promising benefit and tolerability of combination of Atezo + chemotherapy + LDRT in pts with ES-SCLC. Here we report the primary efficacy and safety results of this study. Methods: The MATCH study was a single-arm phase II trial conducted in 8 centers across China. Previously untreated ES-SCLC pts with measureable disease per RECIST v1.1 at baseline, age≥18, ECOG 0-1 were eligible. Atezo (1200 mg IV, D1) + Cisplatin (75 mg/m2 IV, D1)/Carboplatin (AUC = 5 IV, D1) +Etoposide (100 mg/m2 IV, D1-D3) were administrated on a 21-day cycle for four cycles. Concurrent LDRT (15 Gy/5f) were conducted from D1-D5 in the first cycle. Then pts received Atezo maintenance until loss of clinical benefit or unacceptable toxicity. The primary endpoint was objective response rate (ORR), defined as the proportion of patients with a complete response or partial response on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. The secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. A Simon’s minimax 2-stage design was adopted. Results: As the cutoff date of 30th Nov. 2022, 56 pts have been enrolled. 49 (87.5%) were males; mean age was 58.9 years with 78.6% pts had ECOG PS of 1. 80.4% pts had smoking history. Most pts were staged T4 (n = 33, 58.9%), N3 (n = 37, 66.1%) and M1(n = 40, 71.4%). Median follow-up was 14.8 months (range: 11.6-17.8 m). The confirmed ORR was 87.5% (95% CI: 75.9%-94.8%), all partial response. DCR was 94.6% (95% CI: 85.1%-98.9%). Median PFS was 6.9 m (95% CI: 5.4-9.3 m). The 6-month and 12-month PFS rate were 56.5% and 27.7%. Median OS was not reached (NR, 95% CI: 13.3m, NR). The 12-month OS rate was 71.9%. The safety profile, analyzed in all 56 pts, was consistent with the previous reports. Neutrophil count decreased (60.7%), white blood cell count decreased (58.9%) and platelet count decreased (23.2%) were the most common grade (G) 3-4 adverse events (AE). G5 AE occurred in 1 pt (pneumonia and pulmonary embolism). 4 pts experienced AEs leading to treatment discontinuation. IrAEs were reported in 21 (37.5%) pts, most common irAEs were hyperthyroidism (5.4%) and rash (5.4%). Radiation pneumonitis (G1) was observed in 1 pt. Conclusions: Adding LDRT to Atezo + chemotherapy shows impressive antitumor activity, potential survival benefit and well tolerability in 1L treatment of ES-SCLC. Clinical registration: NCT04622228. Citation Format: Lin Zhou, Jianguo Sun, Conghua Xie, Youling Gong, Meijuan Huang, Zhiyong Yuan, Lin Wu, Hui Wang, Nan Bi, Yaping Xu, Jiang Zhu, Yongmei Liu, Yan Zhang, Min Fan, Bingwen Zou, Min Yu, Yanying Li, Feifei Na, Weigang Xiu, Yong Xu, Jin Wang, Xuanwei Zhang, Jianxin Xue, You Lu. Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT219.

Abstract Introduction: Extensive-stage small cell lung cancer (ES-SCLC) is associated with limited treatment options and poor prognosis. Immunotherapy has recently showed robust clinical activity in ES-SCLC. In this double-blind, phase 3 trial, we evaluated adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, in combination with standard chemotherapy (chemo) as first-line treatment for ES-SCLC. Methods: Patients naïve to systemic treatment for ES-SCLC were randomized 1:1 to receive 4-6 cycles of adebrelimab (20 mg/kg, iv, d1, q3w) or placebo with carboplatin (AUC 5, d1, q3w) plus etoposide (100 mg/m2, d1, d2, d3, q3w), followed by maintenance therapy with adebrelimab or placebo. The primary endpoint was overall survival (OS). Results: 462 patients were randomized and treated (adebrelimab+chemo, n=230; placebo+chemo, n=232). As of Oct 08, 2021, with an median follow-up of 13.5 mo (all patients; 22.5 mo for patients alive), OS was significantly prolonged with adebrelimab+chemo vs placebo+chemo (median, 15.3 mo [95% CI 13.2-17.5] vs 12.8 mo [95% CI 11.3-13.7]; hazard ratio [HR], 0.72 [95% CI 0.58-0.90], 1-sided p=0.0017); OS rate was 62.9% vs 52.0% at 12 mo and 31.3% vs 17.2% at 24 mo. Progression-free survival (PFS) per independent review committee (IRC) was 5.8 mo (95% CI 5.6-6.9) with adebrelimab+chemo vs 5.6 mo (95% CI 5.5-5.7) with placebo+chemo (HR 0.67, 95% CI 0.54-0.83); PFS rate was 49.4% vs 37.3% at 6 mo and 19.7% vs 5.9% at 12 mo. Objective response rate (ORR) and duration of response (DoR) also favored the adebrelimab+chemo group (Table 1). Grade ≥3 treatment-related adverse events occurred in 85.7% vs 84.9% of patients with adebrelimab+chemo vs placebo+chemo, with the most common (frequency ≥5%) being hematological toxicities in both groups. Conclusions: The addition of adebrelimab to chemotherapy significantly improved OS with an acceptable safety profile, supporting this combination as a new first-line treatment option for ES-SCLC. Efficacy outcomes Adebrelimab+Chemo (n=230) Placebo+Chemo (n=232) Median OS (95% CI), mo 15.3 (13.2-17.5) 12.8 (11.3-13.7) HR (95% CI)*, 1-sided log-rank p 0.72 (0.58-0.90); p=0.0017 12-mo OS rate (95% CI), % 62.9 (56.3-68.8) 52.0 (45.4-58.2) 24-mo OS rate (95% CI), % 31.3 (24.9-37.9) 17.2 (12.1-23.0) Median PFS (95% CI), mo 5.8 (5.6-6.9) 5.6 (5.5-5.7) HR (95% CI)*, 1-sided log-rank p 0.67 (0.54-0.83); p <0.0001 6-mo PFS rate (95% CI), % 49.4 (42.4-56.0) 37.3 (30.7-43.9) 12-mo PFS rate (95% CI), % 19.7 (14.5-25.5) 5.9 (3.1-10.1) IRC-assessed ORR (95% CI), % 70.4 (64.1-76.3) 65.9 (59.5-72.0) Median DoR (95% CI), mo 5.6 (4.6-6.7) 4.6 (4.3-5.5) *Stratified Cox proportional-hazards model Citation Format: Ying Cheng, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Huiqing Yu, Chengping Hu, Wenhua Zhao, Jian Zhao, Gang Wu, Dingzhi Huang, Chengshui Chen, Cuimin Ding, Baihong Zhang, Xiuwen Wang, Hui Luo, Baolan Li, Ben Zhang, Haowen Li, Ke Ma. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT038.

李紹宏.
"2006年8月"
論文(哲學碩士)--香港中文大学, 2006.
參考文獻(leaves 243-262).
"2006 nian 8 yue"
Abstracts in Chinese and English.
Li Shaohong.
Lun wen (zhe xue shuo shi)--Xianggang Zhong wen da xue, 2006.
Can kao wen xian (leaves 243-262).
Chapter 第一章： --- 導言 --- p.1
Chapter 1.1 --- 研究背景：香港政治文化與國民教育取向 --- p.2
Chapter 1.2 --- 教師團體 --- p.7
Chapter 1.2.1. --- 教協簡介 --- p.7
Chapter 1.2.2 --- 教聯簡介 --- p.9
Chapter 1.3 --- 過渡期的政治變化與國民教育的關係 --- p.11
Chapter 1.4 --- 回歸前後的國民教育議題論爭 --- p.16
Chapter 1.5 --- 研究意義 --- p.33
Chapter 1.6 --- 章節安排 --- p.34
Chapter 第二章： --- 硏究理論 --- p.36
Chapter 2.1 --- 「民族主義」簡介 --- p.36
Chapter 2.2 --- 「中國」分析-回應西方民族主義理論 --- p.39
Chapter 2.2.1 --- 對「中國」的質疑 --- p.40
Chapter 2.2.2 --- 杜贊奇與葛兆光等理論 --- p.42
Chapter 2.2.3 --- 「文化中國」的認同 --- p.47
Chapter 2.2.4 --- 小結 --- p.49
Chapter 2.3 --- 身份認同 --- p.49
Chapter 2.3.1 --- 有關「身份認同」 --- p.50
Chapter 2.3.2 --- 有關「民族認同」 --- p.51
Chapter 2.4 --- 中國民族主義：對外戰爭與「創傷記憶」的民族意識 --- p.54
Chapter 2.5 --- 「創傷記憶」與「驕傲盛世」回憶的民族主義--中國人身份的回溯 --- p.58
Chapter 第三章： --- 研究設計 --- p.64
Chapter 3.1 --- 硏究問題 --- p.64
Chapter 3.2 --- 硏究起點 --- p.65
Chapter 3.3 --- 硏究對象 --- p.67
Chapter 3.3.1 --- 《教協報》及《香港教育》簡介 --- p.67
Chapter 3.3.2 --- 本硏究的選材及標記 --- p.67
Chapter 3.4 --- 硏究方法 --- p.68
Chapter 3.4.1 --- 質化研究法(Qualitative research) --- p.68
Chapter 3.4.2 --- 符號學分析方法 --- p.69
Chapter 第四章、 --- 神話的建立過程-對外仇恨的民族主義與國民教育（一） --- p.82
Chapter 4.1 --- 引言 --- p.82
Chapter 4.2 --- 教協 --- p.83
Chapter 4.2.1 --- 反日愛國與符號分析 --- p.83
Chapter 4.2.2 --- 反日與國民教育 --- p.89
Chapter 4.3 --- 教聯 --- p.92
Chapter 4.3.1 --- 反日愛國與符號分析 --- p.92
Chapter 4.3.2 --- 反日與國民教育 --- p.94
Chapter 4.4 --- 小結 --- p.96
Chapter 第五章、 --- 神話的建立過程-對外仇恨的民族主義與國民教育(二） --- p.99
Chapter 5.1 --- 引言 --- p.99
Chapter 5.2 --- 教協 --- p.99
Chapter 5.2.1 --- 反日愛國與符號分析 --- p.100
Chapter 5.2.2 --- 反日與國民教育-理性神話 --- p.103
Chapter 5.3 --- 教聯 --- p.107
Chapter 5.3.1 --- 反日愛國與符號分析 --- p.107
Chapter 5.3.2 --- 反曰與國民教育 --- p.108
Chapter 5.4 --- 小結 --- p.109
Chapter 第六章 --- 三個神話的確立 --- p.112
Chapter 6.1 --- 文字及圖片分析 --- p.112
Chapter 6.1.1 --- 系譜軸(Paradigm) --- p.112
Chapter 6.1.2 --- 毗鄰軸(Syntagm) --- p.113
Chapter 6.2 --- 歌曲及語言分析 --- p.118
Chapter 6.2.1 --- 歌曲介紹 --- p.119
Chapter 6.2.2 --- 符號分析 --- p.124
Chapter 6.3 --- 三個神話的建立 --- p.130
Chapter 6.3.1 --- 神話的建構過程 --- p.130
Chapter 6.3.2 --- 神話的延伸 --- p.136
Chapter 6.4 --- 小結 --- p.140
Chapter 第七章： --- 血緣神話認同-八九民運 --- p.144
Chapter 7.1 --- 引言 --- p.144
Chapter 7.2. --- 教協愛國及民主想像 --- p.144
Chapter 7.3. --- 教聯黨國不分的矛盾 --- p.157
Chapter 7.3.1 --- 對中共的批評與隱晦 --- p.159
Chapter 7.3.2 --- 「自我失語」與「失憶」的教聯六四歷史 --- p.164
Chapter 7.3.3 --- 教導六四史的方法--客觀理性的歷史教育還是失憶教育？ --- p.166
Chapter 第八章 --- 回蹄神話(一）教聯 --- p.174
Chapter 8.1 --- 引言 --- p.174
Chapter 8.2 --- 民族恥´辱ؤ道德與回歸 --- p.177
Chapter 8.3 --- 奴化教育-救贖與回歸 --- p.186
Chapter 第九章 --- 回歸神話（二)教協 --- p.201
Chapter 9.1 --- 引言 --- p.201
Chapter 9.2 --- 民族恥辱-道德與回歸 --- p.201
Chapter 9.3 --- 回歸矛盾-血緣神話 --- p.205
Chapter 9.4 --- 小結-教聯及教協回歸的取態 --- p.216
Chapter 第十章 --- 結論 --- p.225
Chapter 10.1 --- 總結--回應第一個問題 --- p.225
Chapter 10.2 --- 後現代的質疑 --- p.226
Chapter 10.3 --- 批判與國民教育-回應問題二 --- p.229
Chapter 10.4 --- 研究的起點與啓示-民族身份的反思、教師的反省 --- p.233
Chapter 10.5 --- 硏究的貢獻、限制與啓發 --- p.236
Chapter 10.5.1 --- 硏究的貢獻及特色 --- p.237
Chapter 10.5.2 --- 研究限制 --- p.237
Chapter 10.5.3 --- 未及的討論 --- p.240
Chapter 10.6 --- 後記 --- p.241
參考資料 --- p.243